St. Jude Medical
This article was originally published in The Gray Sheet
Executive Summary
Mechanical heart valve manufacturer announces it will continue a stock repurchase program authorized by its board of directors in July ("The Gray Sheet" July 20, 1992, p. 24). Under the program, the company may repurchase up to 5% of its outstanding common stock, or approximately 2.4 mil. of the roughly 48 mil. shares outstanding. Only 265,000 shares have been repurchased to date under the program. St. Jude President and CEO Ronald Matricaria says the continuation of the repurchase program stems from the firm's belief that its stock is "significantly undervalued." He notes that "anticipation of the Clinton Administration's reform proposals, coupled with the prospect of an increasingly competitive heart valve market, has resulted in a depression of our stock price".
You may also be interested in...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.